Business Description
Anxo Pharmaceutical Co Ltd
8th Floor-3, Nanjing East Road, No. 206, Section 2, Taipei City, TWN
Compare
Compare
Traded in other countries / regions
6677.Taiwan
Description
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.28 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 1.12 | |||||
| Debt-to-EBITDA | 7.35 | |||||
| Interest Coverage | 3.12 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.21 | |||||
| Beneish M-Score | -2.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -3.5 | |||||
| 3-Year EBITDA Growth Rate | -7.4 | |||||
| 3-Year EPS without NRI Growth Rate | -14.4 | |||||
| 3-Year Book Growth Rate | 6 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.15 | |||||
| 9-Day RSI | 56.13 | |||||
| 14-Day RSI | 54.94 | |||||
| 6-1 Month Momentum % | -20.08 | |||||
| 12-1 Month Momentum % | -18.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.49 | |||||
| Quick Ratio | 0.98 | |||||
| Cash Ratio | 0.49 | |||||
| Days Inventory | 187.3 | |||||
| Days Sales Outstanding | 75.68 | |||||
| Days Payable | 52.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.3 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 40.24 | |||||
| Operating Margin % | 4.84 | |||||
| Net Margin % | 2.33 | |||||
| ROE % | 2.67 | |||||
| ROA % | 1.01 | |||||
| ROIC % | 2.13 | |||||
| ROC (Joel Greenblatt) % | 2.69 | |||||
| ROCE % | 2.57 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 51 | |||||
| PE Ratio without NRI | 51 | |||||
| Price-to-Owner-Earnings | 25 | |||||
| PEG Ratio | 1.92 | |||||
| PS Ratio | 1.2 | |||||
| PB Ratio | 1.34 | |||||
| Price-to-Tangible-Book | 1.42 | |||||
| Price-to-Free-Cash-Flow | 24.23 | |||||
| Price-to-Operating-Cash-Flow | 12.59 | |||||
| EV-to-EBIT | 42.37 | |||||
| EV-to-EBITDA | 14.1 | |||||
| EV-to-Revenue | 1.91 | |||||
| EV-to-FCF | 38.02 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.04 | |||||
| Price-to-Graham-Number | 1.79 | |||||
| Earnings Yield (Greenblatt) % | 2.36 | |||||
| Forward Rate of Return (Yacktman) % | 14.16 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 824.1 | ||
| EPS (TTM) (NT$) | 0.4 | ||
| Beta | 0.15 | ||
| Volatility % | 15.36 | ||
| 14-Day RSI | 54.94 | ||
| 14-Day ATR (NT$) | 0.534126 | ||
| 20-Day SMA (NT$) | 19.865 | ||
| 12-1 Month Momentum % | -18.43 | ||
| 52-Week Range (NT$) | 16.3 - 26.25 | ||
| Shares Outstanding (Mil) | 48.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Anxo Pharmaceutical Co Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||